Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the Notice of ....

Aspira Pathlab & Diagnostics Limited Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086 Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086 CIN: L85100MH1973PLC289209 Date: August 31, 2026 Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001. Security Code: 540788 Security ID: ASPIRA Sub: Submission of Annual Report under Regulation 34 of the SEBI (LODR) Regulations, 2015 Dear Sir/Madam, Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the Notice of the 53rd AGM and the Annual Report for the financial year 2025-26 including the Audited Financial Statements for the year ended March 31, 2026 (“Annual Report”), being sent by email to those members whose email addresses are registered with the Company/RTA/Depository Participant(s). In compliance with the relevant MCA Circulars and SEBI Circulars, the Annual Report for the financial year ended 31st March, 2026 comprising the standalone financial statements for the financial year 2025-26, Board's Report, Auditors' Report and other documents required to be attached thereto along with the Notice of 53rd AGM is being sent to all the members of the Company whose email addresses are registered with the Company/ MUFG Intime India Private Limited, Registrar & Transfer Agent (RTA) of the Company and the Depositories. The Notice of the 53rd AGM and the Annual Report are also being uploaded on the website of the Company at https://www.aspiradiagnostics.com/ You are requested to kindly take note of the same. Thanking You, For and on behalf of Aspira Pathlab & Diagnostics Limited Neetu Maurya Company Secretary & Compliance Officer INDIA’S FIRST 0227197 5756, 022 2513 9090 www.aspiradiagnostics.com FULLY INTEGRATED LAB support@aspiradiagnostics.com │info@aspiradiagnostics.com ASPIRA PATHLAB & DIAGNOSTICS LIMITED ANNUAL REPORT 2025-2026 CORPORATE INFORMATION BOARD OF DIRECTORS Dr. Haseeb A. Drabu Chairman & Independent Director Dr. Pankaj J. Shah Managing Director Mrs. Kiran Raghavendra Awasthi Independent Director Mr. Nikunj V. Mange Executive Director Dr. Manas R. Mengar Independent Director Mr. Vaibhav Odhekar D irector KEY MANAGERIAL PERSONNEL Dr. Pankaj J. Shah Chief Executive Mr. Balkrishna S. Talawadekar Chief Financial Officer Mrs. Neetu Maurya Company Secretary & Compliance Officer STATUTORY AUDITORS SECRETARIAL AUDITORS M/s. Sarda Soni Associates LLP M/s. Nilesh A. Pradhan & Co., LLP Practicing Chartered Accountants Practicing Company Secretaries INTERNAL AUDITORS M/s. Vishal J. Bhanushali & Associates Chartered Accountants REGISTRAR & SHARE TRANSFER AGENT PRINCIPAL BANKER MUFG Intime India Private Limited Bank of Baroda (Formerly Link Intime India Private Limited) HDFC Bank C 101, Embassy, 247 Park, L B S Marg, Vikhroli (West), Mumbai 400 083 Tel No: +91 -8108116767 Fax No.: +91- 22 49186060 E-mail Id: rnt.helpdesk@in.mpms.mufg.com Website: www.in.mpms.mufg.com REGISTERED OFFICE CORPORATE OFFICE Flat No. 2, R.D. Shah Building, 6 & 7 , Bhaveshwar Arcade, Shraddanand Road, Near Shreyas Junction LBS Marg, Opp. Ghatkopar Railway Station, Behind Saraswat Bank, Ghatkopar (West), Mumbai -400086, India Ghatkopar (West), Mumbai-400086, India Phone: 022 - 71975756/5656 E-Mail: info@aspiradiagnostics.com Website: www.aspiradiagnostics.com ASPIRA PATHLAB & DIAGNOSTICS LIMITED ANNUAL REPORT 2025-2026 Aspira Pathlab & Diagnostics Limited CIN: L85100MH1973PLC289209 Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400086 Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction, LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086 Contact No:0227197 5756, 022 2513 9090 Website: www.aspiradiagnostics.com Email: info@aspiradiagnostics.com NOTICE NOTICE IS HEREBY GIVEN THAT THE 53rd ANNUAL GENERAL MEETING (“AGM”) OF THE MEMBERS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED (“COMPANY”) WILL BE HELD ON FRIDAY, SEPTEMBER 25, 2026 AT 02.00 P.M (IST) THROUGH VIDEO CONFERENCING (“VC”) / OTHER AUDIO VISUAL MEANS (“OAVM”) FACILITY TO TRANSACT THE FOLLOWING BUSINESSES: ORDINARY BUSINESS: 1. To consider and adopt: Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 together with the reports of the Board of Directors and Auditors thereon and 2. To appoint a Director in place of Mr. Nikunj V Mange, (DIN:08489442) who retires by rotation and being eligible, offers himself for re- appointment. To consider and if thought fit, to pass with or without modification(s),the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of section 152 of the Companies Act, 2013 , Mr. Nikunj V Mange, (DIN:08489442) who retires by rotation and being eligible offers himself for reappointment, be and is hereby re-appointed as a director of the company.” SPECIAL BUSINESS: 3. To consider and approve material related party transaction with M/s. Yashraj Research Foundation. To consider and if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution: “RESOLVED THAT pursuant to Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (the “SEBI Listing Regulations”) and Section 188 of the Companies Act, 2013 (the “Act”), if any, and to the extent applicable, and other applicable provisions of the Act read with the Companies (Meetings of Board and its Powers) Rules, 2014 including any amendments, statutory modifications and/or re-enactment thereof for the time being in force, read with the Company’s Policy on dealing with Related Party Transactions, and subject to such other laws, rules and regulations as may be applicable in this regard and on the basis of the Audit Committee and approval of the Board of Directors of the Company, consent of the members be and is hereby accorded to the Board of Directors (the “Board”, which term shall include any of the committees thereof) of the Company to enter into any and all material related party transactions/contracts/arrangements whether by way of an individual transaction or series of ASPIRA PATHLAB & DIAGNOSTICS LIMITED ANNUAL REPORT 2025-2026 transactions taken together with Yashraj Research Foundation. (“YRF”), a ‘related party’ as defined in Regulation 2(1)(zb) of the SEBI Listing Regulations, inter-alia, for entering into transactions as detailed in the explanatory statement to this resolution, on such terms and conditions as the Board, in its absolute discretion, may deem fit, provided that the aggregate outstanding value of all such material related party transactions/contracts/ arrangements shall at any point of time, not exceed Rs. 5 Crores (Rupees Five Crores Only), provided that the said transactions shall be at the arm’s length basis and in the ordinary course of business. RESOLVED FURTHER THAT the powers be delegated to the Board of the Company and the Board is hereby authorised to negotiate, finalise agree the terms and conditions of the aforesaid sales of services and to do all such acts, deeds and things as may be necessary and incidental including signing and/or execution of any deeds / documents / undertakings / agreements / papers / writings for giving effect to this Resolution.” 4: Re-designation of Executive Director Mr. Nikunj Velji Mange (DIN: 08489442) as “Managing Director” of the company. To consider and, if thought fit, to pass with or without modification(s), the following Resolution as a Special Resolution: “RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 and other applicable provisions, if any, of the Companies Act, 2013 (the Act) (including any statutory modification or re- enactment thereof for the time bein [Showing first 8,000 characters — download PDF for full document]